Achaogen Company Profile (NASDAQ:AKAO)

About Achaogen (NASDAQ:AKAO)

Achaogen logoAchaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AKAO
  • CUSIP: N/A
  • Web: www.achaogen.com
Capitalization:
  • Market Cap: $668.97 million
  • Outstanding Shares: 42,233,000
Average Prices:
  • 50 Day Moving Avg: $17.84
  • 200 Day Moving Avg: $21.63
  • 52 Week Range: $3.68 - $27.79
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.78
  • P/E Growth: -0.08
Sales & Book Value:
  • Annual Revenue: $35.51 million
  • Price / Sales: 18.84
  • Book Value: $4.23 per share
  • Price / Book: 3.74
Profitability:
  • EBIDTA: ($68,050,000.00)
  • Net Margins: -281.88%
  • Return on Equity: -86.24%
  • Return on Assets: -51.32%
Debt:
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 8.37%
  • Quick Ratio: 8.37%
Misc:
  • Average Volume: 703,339 shs.
  • Beta: 1.61
  • Short Ratio: 10.44
 

Frequently Asked Questions for Achaogen (NASDAQ:AKAO)

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How were Achaogen's earnings last quarter?

Achaogen, Inc. (NASDAQ:AKAO) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.18. The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.69 million. Achaogen had a negative net margin of 281.88% and a negative return on equity of 86.24%. Achaogen's revenue for the quarter was down 85.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.87) earnings per share. View Achaogen's Earnings History.

Where is Achaogen's stock going? Where will Achaogen's stock price be in 2017?

10 brokers have issued 12 month price targets for Achaogen's stock. Their forecasts range from $10.00 to $30.00. On average, they anticipate Achaogen's share price to reach $26.00 in the next year. View Analyst Ratings for Achaogen.

What are analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:

  • 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (7/17/2017)
  • 2. Cowen and Company analysts commented, "We are assuming coverage of AKAO with an Outperform." (5/5/2017)
  • 3. Needham & Company LLC analysts commented, "Achaogen mgmt provided a 4Q16 corporate update yesterday. Company remains on track for plazomicin NDA submission 2H17. Details around manufacturing/ CMC were provided, including role for Pfizer McPherson facility in fill/ finish. An FDA Warning Letter was issued to Pfizer last month for matters unrelated to plazomicin at facility. We assume resolution is likely before PDUFA date in 2018. We await additional information on new oral beta-lactam/ BLI cUTI program (C-Scape), but believe commercial opportunity for oral drug in this indication is one of most attractive areas in antibiotic space." (3/15/2017)
  • 4. Aegis analysts commented, "Yesterday after market close, Achaogen announced fourth quarter results, reporting revenue of $10.7 mil vs. street consensus estimates of $12.4 mil and GAAP-EPS of $(1.04) vs. consensus of $(0.49). The EPS miss comes primarily from a $16.9 mil expense recorded in the fourth quarter related to changes in warrants and derivative liabilities that was associated with the capital raise completed in June, 2016. Achaogen is a clinical stage development company, as such we believe the financials are less important, milestones and catalysts tend to drive valuation for these types of companies." (3/15/2017)

Who are some of Achaogen's key competitors?

Who are Achaogen's key executives?

Achaogen's management team includes the folowing people:

  • Bryan E. Roberts Ph.D., Chairman of the Board
  • Kenneth J. Hillan, President, Chief Executive Officer, Director
  • Blake Wise, President, Chief Operating Officer
  • Tobin Schilke, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
  • Lee Swem, Senior Vice President, Chief Scientific Officer
  • Zeryn Sarpangal, Senior Vice President - Corporate and People Strategy
  • Janet Dorling, Chief Commercial Officer
  • John C. Doyle, Director
  • Halley E. Gilbert Esq., Director
  • Kent E. Lieginger, Director

Who owns Achaogen stock?

Achaogen's stock is owned by a number of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (14.55%), FMR LLC (12.64%), State Street Corp (3.97%), Vanguard Group Inc. (3.93%), Versant Venture Management LLC (3.57%) and TimesSquare Capital Management LLC (3.04%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.

Who sold Achaogen stock? Who is selling Achaogen stock?

Achaogen's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, EAM Investors LLC, Sphera Funds Management LTD., Goldman Sachs Group Inc., Nicholas Investment Partners LP, AXA, Fiera Capital Corp and Ameriprise Financial Inc.. Company insiders that have sold Achaogen stock in the last year include Blake Wise, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Insider Buying and Selling for Achaogen.

Who bought Achaogen stock? Who is buying Achaogen stock?

Achaogen's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, TimesSquare Capital Management LLC, Franklin Resources Inc., Vanguard Group Inc., Northern Trust Corp, Lord Abbett & CO. LLC, Artal Group S.A. and Farallon Capital Management LLC. View Insider Buying and Selling for Achaogen.

How do I buy Achaogen stock?

Shares of Achaogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achaogen's stock price today?

One share of Achaogen stock can currently be purchased for approximately $15.84.


MarketBeat Community Rating for Achaogen (NASDAQ AKAO)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  310
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Achaogen (NASDAQ:AKAO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.90)
Consensus Price Target: $26.00 (64.14% upside)

Analysts' Ratings History for Achaogen (NASDAQ:AKAO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017MizuhoInitiated CoverageBuy$28.00HighView Rating Details
8/4/2017Stifel NicolausReiterated RatingBuy$30.00HighView Rating Details
6/15/2017HC WainwrightInitiated CoverageBuy -> Buy$29.00MediumView Rating Details
5/15/2017Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
4/24/2017WedbushReiterated RatingOutperform$28.00HighView Rating Details
3/30/2017AegisDowngradeBuy -> Hold$29.00LowView Rating Details
3/15/2017Needham & Company LLCReiterated RatingBuy$29.00MediumView Rating Details
1/24/2017GuggenheimReiterated RatingBuy$30.00N/AView Rating Details
1/4/2017Leerink SwannInitiated CoverageOutperform$21.00N/AView Rating Details
9/26/2016SunTrust Banks, Inc.Reiterated RatingBuy$10.00N/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Achaogen (NASDAQ:AKAO)
Earnings by Quarter for Achaogen (NASDAQ:AKAO)
Earnings History by Quarter for Achaogen (NASDAQ AKAO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.60)($0.78)$2.69 million$1.30 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.54)($0.93)$3.81 million$7.46 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.49)($1.04)$13.33 million$10.73 millionViewN/AView Earnings Details
11/7/2016Q3($0.61)($0.41)$8.72 million$16.05 millionViewListenView Earnings Details
8/8/2016Q2($0.67)($0.87)$5.58 million$9.14 millionViewN/AView Earnings Details
3/15/2016Q414($0.58)($0.61)$5.33 million$4.70 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.46)($0.48)$5.10 million$4.48 millionViewN/AView Earnings Details
8/10/2015Q2 2015($0.20)($0.05)$8.65 million$12.04 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.25)($0.34)$5.00 million$4.88 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.33)($0.27)$4.96 million$4.26 millionViewN/AView Earnings Details
11/10/2014Q314($0.18)($0.47)$6.00 million$4.52 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.19)($0.20)$5.99 million$5.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.21)($1.00)$5.39 million$6.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Achaogen (NASDAQ:AKAO)
2017 EPS Consensus Estimate: ($2.57)
2018 EPS Consensus Estimate: ($3.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.56)($0.48)($0.54)
Q2 20174($0.71)($0.58)($0.66)
Q3 20174($0.88)($0.62)($0.70)
Q4 20174($0.86)($0.59)($0.68)
Q1 20181($0.63)($0.63)($0.63)
Q2 20181($0.69)($0.69)($0.69)
Q3 20181($0.81)($0.81)($0.81)
Q4 20181($0.91)($0.91)($0.91)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Achaogen (NASDAQ:AKAO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Achaogen (NASDAQ:AKAO)
Insider Ownership Percentage: 13.80%
Institutional Ownership Percentage: 84.12%
Insider Trades by Quarter for Achaogen (NASDAQ:AKAO)
Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)
Insider Trades by Quarter for Achaogen (NASDAQ:AKAO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Tobin SchilkeCFOSell2,066$21.53$44,480.98View SEC Filing  
1/26/2017Gary LoebGeneral CounselSell521$16.78$8,742.38View SEC Filing  
1/26/2017Ian FriedlandInsiderSell695$16.78$11,662.10View SEC Filing  
1/26/2017Kenneth J. HillanCEOSell1,431$16.78$24,012.18View SEC Filing  
1/26/2017Tobin SchilkeCFOSell955$16.78$16,024.90View SEC Filing  
1/26/2017Zeryn SarpangalVPSell781$16.78$13,105.18View SEC Filing  
12/19/2016Equity Opportunities Iv GrowthMajor ShareholderBuy500,000$13.50$6,750,000.00View SEC Filing  
9/27/2016Blake WiseCOOSell3,632$4.30$15,617.60View SEC Filing  
9/27/2016Zeryn SarpangalVPSell1,069$4.30$4,596.70View SEC Filing  
3/17/2016Ian FriedlandInsiderSell1,772$3.22$5,705.84View SEC Filing  
3/17/2016Kenneth J HillanCEOSell3,572$3.22$11,501.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Achaogen (NASDAQ:AKAO)
Latest Headlines for Achaogen (NASDAQ:AKAO)
Source:
DateHeadline
globenewswire.com logoAchaogen Adds Liz Bhatt as Chief Business Officer - GlobeNewswire (press release)
globenewswire.com - September 20 at 3:36 PM
streetinsider.com logoAchaogen (AKAO) Appoints Liz Bhatt as Chief Business Officer - StreetInsider.com
www.streetinsider.com - September 18 at 9:05 PM
finance.yahoo.com logoETFs with exposure to Achaogen, Inc. : September 18, 2017
finance.yahoo.com - September 18 at 9:05 PM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $1.69 Million
www.americanbankingnews.com - September 17 at 3:54 AM
americanbankingnews.com logo-$0.72 Earnings Per Share Expected for Achaogen, Inc. (AKAO) This Quarter
www.americanbankingnews.com - September 15 at 8:44 PM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 9 at 6:26 AM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Now Covered by Analysts at Mizuho
www.americanbankingnews.com - September 6 at 5:18 PM
finance.yahoo.com logoAchaogen, Inc. :AKAO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 5 at 4:56 PM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - August 22 at 11:58 PM
globenewswire.com logoAchaogen Announces New Employment Inducement Grants - GlobeNewswire (press release)
globenewswire.com - August 21 at 8:54 PM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 15 at 6:50 AM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - August 12 at 3:58 PM
globenewswire.com logoAchaogen to Present at the Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - August 8 at 8:42 PM
finance.yahoo.com logoAchaogen to Present at the Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 8:42 PM
americanbankingnews.com logoStifel Nicolaus Reaffirms Buy Rating for Achaogen, Inc. (NASDAQ:AKAO)
www.americanbankingnews.com - August 5 at 11:34 AM
americanbankingnews.com logoBIOVERATIV INC (BIVV) vs. Achaogen (NASDAQ:AKAO) Head-To-Head Review
www.americanbankingnews.com - August 5 at 8:30 AM
americanbankingnews.com logoAchaogen, Inc. (NASDAQ:AKAO) Releases Earnings Results
www.americanbankingnews.com - August 4 at 4:20 PM
finance.yahoo.com logoEdited Transcript of AKAO earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 4:01 PM
finance.yahoo.com logoAchaogen reports 2Q loss
finance.yahoo.com - August 3 at 9:56 PM
finance.yahoo.com logoAchaogen, Inc. – Value Analysis (NASDAQ:AKAO) : August 4, 2017
finance.yahoo.com - August 3 at 9:56 PM
globenewswire.com logoAchaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - August 3 at 4:54 PM
finance.yahoo.com logoAchaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 3 at 4:54 PM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - July 31 at 4:47 PM
americanbankingnews.com logoAchaogen, Inc. (NASDAQ:AKAO) to Release Earnings on Monday
www.americanbankingnews.com - July 31 at 8:05 AM
americanbankingnews.com logoQ2 2017 Earnings Forecast for Achaogen, Inc. (NASDAQ:AKAO) Issued By Wedbush
www.americanbankingnews.com - July 31 at 7:02 AM
prnewswire.com logoHow These Biotech Stocks are Performing? -- Intrexon, 22nd Century, Corcept Therapeutics, and Achaogen - PR Newswire (press release)
www.prnewswire.com - July 26 at 3:43 PM
nasdaq.com logoAchaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant ... - Nasdaq
www.nasdaq.com - July 25 at 3:35 PM
nasdaq.com logoAchaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant ... - Nasdaq
www.nasdaq.com - July 25 at 3:35 PM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $2.30 Million
www.americanbankingnews.com - July 22 at 9:14 AM
americanbankingnews.com logoAchaogen, Inc. (NASDAQ:AKAO) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 21 at 7:40 AM
americanbankingnews.com logoAchaogen, Inc. (NASDAQ:AKAO) Expected to Post Earnings of -$0.63 Per Share
www.americanbankingnews.com - July 20 at 6:26 PM
finance.yahoo.com logoAchaogen, Inc. breached its 50 day moving average in a Bearish Manner : AKAO-US : July 20, 2017
finance.yahoo.com - July 20 at 5:04 PM
americanbankingnews.com logoCritical Analysis: Cerulean Pharma (CERU) vs. Achaogen (NASDAQ:AKAO)
www.americanbankingnews.com - July 18 at 1:17 PM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 17 at 8:26 PM
americanbankingnews.com logoShort Interest in Achaogen, Inc. (AKAO) Grows By 55.2%
www.americanbankingnews.com - July 14 at 7:20 AM
streetinsider.com logoAchaogen (AKAO) Names Dr. Karen Bernstein to its Board of Directors - StreetInsider.com
www.streetinsider.com - July 13 at 9:28 PM
americanbankingnews.com logoAchaogen, Inc. (NASDAQ:AKAO) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - July 11 at 9:38 PM
americanbankingnews.com logoAchaogen, Inc. (NASDAQ:AKAO) Upgraded at BidaskClub
www.americanbankingnews.com - July 8 at 8:58 PM
finance.yahoo.com logoETFs with exposure to Achaogen, Inc. : July 4, 2017
finance.yahoo.com - July 4 at 5:36 PM
americanbankingnews.com logo$2.30 Million in Sales Expected for Achaogen, Inc. (AKAO) This Quarter
www.americanbankingnews.com - June 28 at 11:14 AM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Expected to Announce Earnings of -$0.63 Per Share
www.americanbankingnews.com - June 26 at 2:22 PM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 26 at 8:00 AM
finance.yahoo.com logoAchaogen, Inc. breached its 50 day moving average in a Bullish Manner : AKAO-US : June 22, 2017
finance.yahoo.com - June 22 at 12:23 PM
americanbankingnews.com logoAchaogen, Inc. (AKAO) Research Coverage Started at HC Wainwright
www.americanbankingnews.com - June 17 at 9:04 PM
americanbankingnews.com logoAchaogen, Inc. (AKAO) CFO Tobin Schilke Sells 2,066 Shares
www.americanbankingnews.com - June 14 at 10:48 PM
streetinsider.com logoAchaogen (AKAO) Highlights Data Demonstrating Potential of ... - StreetInsider.com
www.streetinsider.com - June 5 at 11:35 PM
americanbankingnews.com logoAchaogen Inc (AKAO) Expected to Announce Quarterly Sales of $2.33 Million
www.americanbankingnews.com - June 2 at 1:52 PM
finance.yahoo.com logoAchaogen Announces Closing of Public Offering
finance.yahoo.com - May 31 at 8:29 PM
americanbankingnews.com logoAchaogen Inc (AKAO) Expected to Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - May 31 at 10:30 AM
americanbankingnews.com logoAchaogen Inc (AKAO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 8:01 AM

Social

Chart

Achaogen (AKAO) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff